Advances in the last decade in genomic profiling and the identification of druggable targets amenable to biological agents have transformed the management and survival of a subgroup of patients with brain metastasis in non-small-cell lung cancer. In parallel, clinicians have reevaluated the role of whole brain radiotherapy in selected patients with brain metastases to reduce neurocognitive toxicity. Continual progress in this understudied field is required: optimization of the sequence of schedules for therapies in patients with brain metastases of differing genomic profiles, focusing on new strategies to overcome mechanisms of biological resistance and increasing drug penetrability into the central nervous system. This review summarizes the field to date and possible treatment strategies based on current evidence.

中文翻译：

---

非小细胞肺癌脑转移的新兴治疗范例：当前现状和未来挑战的概述。

过去十年中，基因组图谱研究的进展以及适用于生物制剂的可药用靶标的确定，已经改变了非小细胞肺癌脑转移患者亚组的治疗和生存率。同时，临床医生重新评估了全脑放疗在某些脑转移患者中的作用，以减少神经认知毒性。需要在这个尚未得到充分研究的领域中不断取得进展：优化具有不同基因组特征的脑转移患者的治疗方案顺序，重点是克服生物耐药性机制和增加药物对中枢神经系统的渗透性的新策略。这篇综述总结了迄今为止的领域和基于当前证据的可能的治疗策略。